Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

Aberrant NF-κB activity drives oncogenesis and cell survival in multiple myeloma (MM) and many other cancers. However, despite an aggressive effort by the pharmaceutical industry over the past 30 years, no specific IκBα kinase (IKK)β/NF-κB inhibitor has been clinically approved, due to the multiple...

Full description

Bibliographic Details
Main Authors: Laura Tornatore, Daria Capece, Daniel D'Andrea, Federica Begalli, Daniela Verzella, Jason Bennett, Gary Acton, Elizabeth A. Campbell, James Kelly, Michael Tarbit, Nigel Adams, Selina Bannoo, Antonio Leonardi, Annamaria Sandomenico, Domenico Raimondo, Menotti Ruvo, Angela Chambery, Metod Oblak, Magda J. Al-Obaidi, Richard S. Kaczmarski, Ian Gabriel, Heather E. Oakervee, Martin F. Kaiser, Ashutosh Wechalekar, Reuben Benjamin, Jane F. Apperley, Holger W. Auner, Guido Franzoso
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Toxicology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2214750018307169

Internet

http://www.sciencedirect.com/science/article/pii/S2214750018307169

Similar Items